Kayexalate Intake (in Sorbitol) and Jejunal Diverticulitis, a Causative Role or an Innocent Bystander? by Pusztaszeri, Marc et al.
 
Case Rep Gastroenterol 2007;1:144–151 
DOI: 10.1159/000111173 
Published online: December 4, 2007  © 2007 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
Marc Pusztaszeri    Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV)  
Rue du Bugnon 25 
CH–1011 Lausanne (Switzerland) 
Tel. +41 21 314 29 54, Fax +41 21 314 71 15, E-Mail Marc.Pusztaszeri@chuv.ch 
 
144
   
Kayexalate Intake (in Sorbitol) 
and Jejunal Diverticulitis, a 
Causative Role or an Innocent 
Bystander? 
Marc Pusztaszeria    Michel Christodouloub    
Stefania Proiettic    Walter Seelentaga 
Departments of aPathology, bSurgery and cRadiology, Centre Hospitalier 
Universitaire Vaudois (CHUV), Lausanne, Switzerland 
 
Key Words 
Jejunal diverticulosis · Diverticulitis · Kayexalate 
 
Abstract 
Small intestine diverticulosis is a rare entity that is asymptomatic in the majority of cases. 
However, it may cause serious complications, such as infection, hemorrhage, intestinal 
obstruction and diverticulitis. Kayexalate (sodium polystyrene sulfonate) in sorbitol has 
been associated with colonic necrosis and less frequently with upper gastrointestinal 
injuries in a subset of uremic patients treated for hyperkalemia. We report a case of 
jejunal diverticulosis with mucosal injury and diverticulitis in a uremic patient treated 
with Kayexalate and discuss the potential role of Kayexalate in the pathogenesis of 
diverticulitis. 
 
Introduction 
Diverticula of the jejunum and ileum (excluding Meckel’s diverticulum) are rare 
clinicopathological entities and most patients are asymptomatic [1]. Due to the rarity of 
the condition, the diagnosis is difficult and often delayed until complications arise. This 
results in unnecessary morbidity and mortality. 
Kayexalate (sodium polystyrene sulfonate) in sorbitol is used frequently for treatment 
of hyperkalemia and has been associated with colonic necrosis and upper gastrointestinal 
injuries in a subset of uremic patients [2]. Necrosis of the gastrointestinal (GI) tract due to 
Kayexalate in sorbitol is underrecognized by pathologists as well as clinicians. The most 
commonly affected site is the colon. Small intestinal damage related to Kayexalate has 
been described only infrequently in the terminal ileum [3]. We report a case of jejunal  
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diverticulosis with mucosal injury and diverticulitis in a uremic patient treated with 
Kayexalate. To our knowledge, this is the first description of such an association. The two 
conditions and the potential role of Kayexalate in the pathogenesis of diverticulitis are 
discussed. 
Case Report 
A 87-year-old male patient under dialysis for a terminal chronic renal insufficiency was admitted to 
the surgery department for correction of an occlusion located at the vascular access of his left upper 
limb fistulae. There was a history appendectomy, cholecystectomy, radical prostatectomy and of 
ischemic cardiopathy with instable angor that had been relieved by stenting of the left circumflex 
coronary artery placed 2 months earlier. The patient received Sorbisterit-Calcium (calcium-polystyrol) 
with sorbitol among other medications. During the current admission, he developed abdominal pain 
that was more severe in the right hemi-abdomen. White cell count was 15,000 (per mm
3) and CRP was 
260 mg/l. An abdominal CT scan was performed and revealed a small intestinal diverticulosis with 5 
giant diverticula (fig. 1a). The largest was 6.5 cm in diameter. There was an infiltration of mesenteric fat 
around 2 diverticula measuring 5.5 and 3 cm, which was suggestive of diverticulitis. No intestinal 
perforation or free peritoneal gas were seen. On the same day, an exploratory laparotomy was 
performed with resection of a 25-cm-long jejunal segment (fig. 1b). Postoperative evolution was 
unremarkable and the patient was discharged 10 days later. 
Pathologic Evaluation 
A 25-cm-long small intestine segment was received for pathological evaluation. The serosal surface 
was partially covered with a fibrinous exudate but there was no evidence of perforation. Five diverticula 
were identified. The smallest measured 4 × 3.5 × 1.2 cm and the largest 6.5 × 4.5 × 4.4 cm (fig. 2a, b). 
They were all adjacent to the mesenteric insertion. They were filled with green fecaloid material. 
Histological examination showed that the diverticula were in fact pseudo-diverticula, which 
consisted of mucosa and muscularis mucosae invaginating through the muscularis propria (fig. 3). 
However, some pseudo-diverticula also contained some thin and discontinuous smooth muscle bundles 
in addition to the muscularis mucosae (fig. 3d). Multiple ulcerations of various depth and areas of 
transmural necrosis were seen in most diverticula (fig. 3b, c, f). There was a diffuse fibrinous exudate on 
the
 serosal surface (fibrinous peritonitis). Numerous irregular, sharply angulated (broken-glass like) 
crystals were seen adherent on the mucosal side and on the ulcerations (fig. 3c, f, g). They were 
basophilic on routine stain, with a mosaic or striped pattern, and stained bright red on periodic acid 
Schiff (PAS) stain. They were also found in the necrotic wall, and rarely in the exudate on the peritoneal 
surface consistent with microscopic perforations. 
Discussion 
To our knowledge, this is the first description of an association between jejunal 
ulcerated diverticulitis and Kayexalate intake in a uremic patient. In this unusual case, 
Kayexalate might be just an innocent bystander but could also be on the other hand 
implicated to some extent in the pathogenesis of the mucosal injury and diverticulitis. 
Before discussing the possible role of Kayexalate in the pathogenesis of the diverticulitis, 
we will first review the two conditions (ileo-jejunal diverticulosis and Kayexalate related 
GI tract injury) separately. 
Ileo-Jejunal Diverticulosis 
Diverticula of the jejunum and ileum are rare clinical entities in contrast to Meckel’s 
diverticulum, which is fairly common [1, 4, 5]. Reported incidence of ileo-jejunal 
diverticula ranges from 0.3 to 4.5% in autopsy series and from 0.5 to 2.3% in radiological  
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studies and depends largely on examination technique [6]. Highest incidence was found 
either when filling the small bowel with water under moderate pressure in autopsy studies 
or when using enteroclysis in radiological studies. They are more frequently encountered 
in the elderly, with a peak incidence in the sixth and seventh decades, and have a slight 
male predominance [1]. They are preferentially localized to the jejunum (80%), to a lesser 
degree to the ileum (15%) and sometimes they involve both parts (5%). They can measure 
from a few millimeters up to more than 10 cm and tend to be more numerous and larger 
in the proximal jejunum [7, 8], such as in our case. Strictly speaking, in most instances 
they are not true diverticula such as Meckel’s diverticula, which comprise all parts of the 
bowel wall, but they are pseudo-diverticula formed by herniation of mucosa and 
submucosa through the muscular layer of the bowel wall on the mesenteric border of the 
bowel where the arteries enter the intestine. Histologically they are lined by mucosa, 
muscularis mucosae and submucosa and lack a muscularis propria. In contrast, Meckel’s 
diverticula are located on the side opposed to the mesentery, are delineated by mucosa, 
submucosa and muscularis propria and may contain heterotopic mucosa. The 
pathogenesis of small-bowel diverticula is still open to debate. Although they can be 
congenital the vast majority is acquired [8, 9]. The cause of small bowel diverticulosis 
seems to be motor dysfunction of the smooth muscle or the myenteric plexus. The 
resulting intestinal dyskinesia might increase intraluminal pressure that will push the 
mucosa and submucosa through the weakest site of the bowel wall, which are the entry 
points of the blood vessels from the mesentery [8–10]. The predominance of diverticula 
in the jejunum is attributed to the greater diameter of the penetrating jejunal arteries. The 
diverticula usually remain asymptomatic (over 80%) and become evident as an incidental 
finding at the time of surgery, during a radiographic examination or at autopsy. Their 
clinical importance is based on the fact that like colonic diverticulosis they may cause 
serious complications, such as infection, hemorrhage, intestinal obstruction and 
ileovesical fistula. The mortality rate from these complications can be as high as 40%. 
Complications related to the diverticula occur in about 15 to 20% of patients and 
complications or symptoms requiring surgery have been reported to occur in up to 10%. 
The most frequent acute complication of the jejunoileal diverticula is probably 
diverticulitis (with or without perforation), occurring in 2.3 to 6.4% of cases [6]. 
Kayexalate Related GI Tract Injury 
Kayexalate is a cation-exchange resin given orally for the treatment of hyperkalemia. 
The occurrence of GI necrosis due to Kayexalate in sorbitol is well documented [2, 3, 11–
15] and supported by experimental evidence [12]. However, the true incidence of colonic 
necrosis after Kayexalate intake is unknown. Gerstmann et al. noted a 0.27% overall 
incidence, with a higher (1.8%) incidence in the postoperative period [13]. The 
pathogenesis of Kayexalate related GI injury is still unclear. Factors that contribute to this 
entity include uremia, hypovolemia, peripheral vascular disease, and immunosuppressive 
therapy. 
One of the first studies from Lillemoe et al. reported five uremic patients who 
developed catastrophic colonic necrosis that was associated temporally with the use of 
Kayexalate in sorbitol and contributed to death in four of the five patients [12]. That 
study also provided experimental evidence implicating sorbitol rather than Kayexalate as 
the agent responsible for colonic necrosis in a rat model. No pathologic changes 
developed in rats receiving enemas of Kayexalate in water, but transmural colonic 
necrosis developed in six of 10 rats receiving sorbitol enemas. Production of 
prostaglandins may be stimulated
 by sorbitol and could play a part in causing mucosal  
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injury [14]. Previous reports of GI injury associated with administration of Kayexalate in 
sorbitol have focused almost exclusively on colonic or ileocolonic necrosis in patients 
with hyperkalemia [3, 11–15]. More recently, Abraham et al. have shown that Kayexalate 
can also induce upper GI tract injury [2]. 
In the differential diagnosis, Kayexalate crystals also need to be distinguished 
histologically from cholestyramine crystals that look very similar. The distinction is 
important since, in contrast to Kayexalate, cholestyramine has not been associated with 
GI tract injury to date. Both consist of irregular, sharply angulated (broken-glass like) 
fragments of an amorphous substance, but the former are slightly basophilic on routine 
stain with a mosaic or striped pattern. The latter appear bright red on routine stain and 
are more homogeneous, without a mosaic or striped pattern (fig. 3g, h). 
It can be difficult to define the role of Kayexalate in sorbitol in the development of 
mucosal injury and diverticulitis in elderly patients who presents with multiple medical 
problems and who are also at risk for ischemic complications. In our case, while it is 
possible that Kayexalate might be just an innocent bystander in the pathogenesis of the 
diverticulitis, we believe that Kayexalate likely played a role in the diverticulitis and 
mucosal injury either as a causative agent or as a cofactor. The pattern of ulceration and 
diverticulitis present in our case is not the one that is usually seen in diverticulitis in the 
colon or in a Meckel’s diverticulum. The ulcerations were often associated with wall 
necrosis and there was mild acute inflammation which might point to a local ischemia. In 
contrast, the mucosae next to the diverticulitis did not show any sign of ischemia, which 
suggests that bowel segment ischemia is not the cause of the diverticulitis. Furthermore, 
diverticula without Kayexalate deposits were devoid of inflammation. Rashid and 
Hamilton reported similar findings to ours in their study about colonic specimens from 
nine patients with Kayexalate-sorbitol induced colonic necrosis [3]. They described in the 
involved segments mucosal ulceration, dusky mucosal coloration, mural oedema, serosal 
fibrinous exudate, mucosal or transmural necrosis and perforation with luminal 
Kayexalate crystals [3, 11]. 
In the GI tract, diverticula are likely to be sites vulnerable to Kayexalate injury since the 
content in the lumen including Kayexalate crystals and sorbitol is trapped inside the 
diverticula and is more likely to stay in contact with the mucosa for prolonged time. The 
same is also true for any mechanical factors such as tumors or other obstructing lesions 
that delay GI transit and prolong contact between the mucosa and sorbitol, hence 
predisposing to injury. Furthermore, impairment of blood-flow by the pseudodiverticula, 
which compress the branches of the mesenteric blood vessels at the site of passage 
through the muscularis propria, may add additional stress to the mucosa. Since the 
pseudodiverticula wall is also significantly thinner than the normal bowel wall, the risk of 
perforation and peritonitis is also increased. 
In conclusion, in addition to the more commonly reported risk of colonic necrosis, 
Kayexalate in sorbitol could induce injury to other parts of the GI tract, particularly in 
sites where a prolonged contact with the mucosa might be expected. Although the 
histologically visible Kayexalate crystals are not directly responsible for mucosal damage, 
their recognition as a marker for the patient’s ingestion of Kayexalate in sorbitol is a clue 
in providing the correct diagnosis in patients with mucosal injury, which is essential for 
appropriate treatment. 
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Fig. 1. a Axial CT image showing multiple diverticula (white arrows) on the mesenteric border of the 
jejunum, surrounded by inflammatory mesenteric fat. The arrowhead shows the communication 
between one diverticula and the jejunal lumen. b Intraoperative view of the jejunum showing multiple 
diverticula, the largest being partially covered with white fibrinous exudate. 
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Fig. 2. a Macroscopic view of the jejunal segment showing 3 diverticula, adjacent to the mesenteric 
insertion. The serosal surface is covered with white fibrinous exudate. b The diverticula are filled with 
green fecaloid material and their wall is thin. 
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Fig. 3. Wall of a non-inflamed diverticulum (a, d, e) and an inflamed diverticulum (b, c, f). Kayexalate 
crystals (black arrows) are seen only in the lumen (star) and in the wall of the inflamed diverticulum. 
Thin and discontinuous smooth muscle bundles (arrowheads) are seen in the wall of some diverticula 
(d). g, h Close-up views of Kayexalate (g) and cholestyramine crystals (h); the former are basophilic 
with a striped or mosaic pattern and the latter are eosinophilic and more homogeneous (a–c and e–h: 
HE stain; d: Masson Trichrome stain). 
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